Nutcracker Therapeutics, Inc.

The presently described and disclosed technology includes, in one example, a method, comprising: extracting a sequence of a spike protein of a first virus from a first non-human mammal that is previously exposed to an infection by the first virus; identifying a target antigen specific to the spike protein; and injecting an mRNA therapeutic comprising an mRNA encoding the target antigen into a human patient that has antibodies to a second virus.

Apparatuses and methods are described herein for processing polynucleotides in a sealed path environment. The apparatuses include optical sensors to monitor operations and to track material usage for good manufacturing practice.

A system includes an optical sensor and a processor. The optical sensor has a field of view positioned to include a first fluid channel defined by a body. The processor receives a first image including a region of interest of the first fluid channel. The processor further receives a second image including the region of interest of the first fluid channel. The second image is captured after the first image. The processor further generates a comparison of the second image to the first image, generates a binary image using the comparison, and uses the binary image to determine whether a fluid is present in the region of interest of the first fluid channel. If the processor determines that the fluid is present in the region of interest of the first fluid channel, the processor ceases communication of the fluid through the first fluid channel.

The present disclosed and described technology are directed to multimodal mRNA-based immunotherapies that deliver both antigens and immunomodulators. Related formulations, method of administration, and kits are disclosed and described.

A system includes a chip-receiving component, a first fluid processing assembly, a second fluid processing assembly, and a fluid communication pathway. The chip-receiving component is to receive a process chip having microfluidic passageways. The first fluid processing assembly is to communicate fluids to microfluidic passageways of a process chip received by the chip-receiving component. The second fluid processing assembly includes a sample support feature to support sample containers. The second fluid processing assembly also includes a plurality of sampling heads to selectively communicate fluids from sample containers supported by the sample support feature. The fluid communication pathway includes a plurality of conduits to provide fluid communication between the first fluid processing assembly and the plurality of sampling heads. The first fluid processing assembly is to further communicate fluids from the fluid communication pathway to microfluidic passageways of a process chip received by the chip-receiving component.

An example system includes a plurality of scriptable devices, each of which exposes an interface. The system may also comprise a medium storing data indicating, for each of a mapped plurality of device operations, one or more inputs to provide to a corresponding device from the plurality of scriptable devices and a conversion between that device operation and a corresponding application command. In such a system, the medium may also store a plurality of scripts, each of which may have a corresponding scriptable device from the plurality of scriptable devices and may comprise a set of device operations. The system may also comprise a computer to repeatedly preform an operation cycle comprising determining whether an application command should be executed and, when it should, generating a globally unique identifier corresponding to that command and adding that globally unique identifier and a device operation corresponding to that command to a log.

A method includes incubation of an amplification mixture containing uracil-DNA glycosy lase enzyme (UNG enzyme), a deoxyribonucleotide triphosphate (dNTP) mixture, a DNA polymerase, a template including a sequence of interest, and at least one primer pair, inactivation of UNG enzyme in the amplification mixture, and amplification of a sequence of interest to form an in vitro transcription template. The in vitro transcription template may be used to produce a therapeutic polynucleotide.

The present disclosed and described technology are directed to multimodal mRNA-based immunotherapies that deliver both antigens and immunomodulators. Related formulations, method of administration, and kits are disclosed and described.

The disclosure provides materials in the form of nanoparticles containing in vitro-transcribed mRNAs encoding antigenic peptides and personalized medicine methods for treating or preventing diseases such as cancer, an autoimmune disease, an infectious disease, or inflammation, wherein cells of a subject receiving prophylactic or therapeutic treatment are brought into contact with the nanoparticles ex vivo, and the subject's cells process the mRNA. expressing and presenting the encoded product to activate the subject's own T cells. thereby mounting an immune response to the diseased cells. such as cancer cells.

Provided herein are examples of mRNA treatment nanoparticles and methods of using them to treat a patient. An mRNA treatment nanoparticle may include one or more mRNAs encoding a tumor-specific antigen and an immunomodulatory agent; and a delivery vehicle molecule encapsulating the one or more mRNAs.